Table 3.
Pathological findings, prothrombotic states, and features of portal hypertension
| Patient No | Pathological findings | CD34* | Prothrombotic state | Portal vein thrombosis | HVPG (mm Hg) | Gastrointestinal bleeding |
| 1 | Hepatoportal sclerosis | 12.0 | Incomplete investigation | Yes | 7 | Yes |
| 2 | Hepatoportal sclerosis | 12.1 (23.8)† | None | No | 16 | Yes |
| 3 | Hepatoportal sclerosis | 6.3 | None | No | 21 | No |
| 4 | Hepatoportal sclerosis | 19.4 | APL syndrome, protein S, and protein C deficiency | No | NA | No |
| 5 | Hepatoportal sclerosis | NS | None | No | NA | No |
| 6 | Hepatoportal sclerosis | NS | None | Yes | NA | Yes |
| 7 | Hepatoportal sclerosis and perisinusoidal fibrosis | 5.7 | Polycythemia vera | No | 2 | No |
| 8 | Hepatoportal sclerosis and perisinusoidal fibrosis | NS | APL syndrome | Yes | NA | Yes |
| 9 | Hepatoportal sclerosis and nodular regenerative hyperplasia | 6.4 | None | No | NA | No |
| 10 | Hepatoportal sclerosis and nodular regenerative hyperplasia | 7.4 | Protein S deficiency | Yes | NA | No |
| 11 | Hepatoportal sclerosis and nodular regenerative hyperplasia | 7.1 | None | Yes | 9 | Yes |
| 12 | Periportal fibrosis | 2.3 | None | No | 9 | No |
| 13 | Periportal fibrosis | 5.7 | None | No | 1 | No |
| 14 | Periportal fibrosis | 6.8 | Protein S deficiency Latent PMD |
Yes | 2 | Yes |
| 15 | Periportal fibrosis | NS | None | Yes | NA | No |
| 16 | Periportal fibrosis | NS | APL syndrome | Yes | NA | Yes |
| 17 | Periportal fibrosis | NS | Latent PMD | Yes | NA | Yes |
| 18 | Periportal fibrosis | NS | None | No | NA | Yes |
| 19 | Periportal and perisinusoidal fibrosis | 2.4 | Protein S deficiency | No | 10 | No |
| 20 | Periportal and perisinusoidal fibrosis | NS | Protein C deficiency Latent PMD |
Yes | 6 | No |
| 21 | Perisinusoidal fibrosis | 3.4 (2.5)† | Protein S deficiency | Yes | NA | Yes |
| 22 | Perisinusoidal fibrosis | 2.4 | Incomplete study | No | 3 | Yes |
| 23 | Perisinusoidal fibrosis | 3.0 (2.6)† | Latent PMD | No | 2 | Yes |
| 24 | Perisinusoidal fibrosis | 2.3 (5.3)† | Extrahepatic lymphoma | No | 6 | Yes |
| 25 | Perisinusoidal fibrosis | NS | Latent PMD | Yes | NA | Yes |
| 26 | Nodular regenerative hyperplasia | NS | None | Yes | NA | Yes |
| 27 | Nodular regenerative hyperplasia | NS | Protein S deficiency | No | NA | Yes |
| 28 | Unclassified | NS | None | No | NA | Yes |
*CD34, number of vascular section per portal tract marked with this monoclonal antibody.
†Two liver specimens were analysed. The results of both analyses are provided.
HVPG, hepatic venous pressure gradient; APL, antiphospholipid; PMD, primary myeloproliferative disorder; NA, not available; NS, no staining.